POGLUT3 and triple-negative breast carcinoma: POGLUT3 was associated with a lower risk of kidney cancer [OR: 0.71, 95% CI: 0.63 to 0.79; PP4: 0.98] and lung adenocarcinoma [OR: 0.80, 95% CI: 0.73 to 0.89; PP4: 0.99] but an increased risk of both ER- and triple-negative breast cancer.